Cargando…

Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam

BACKGROUND: Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the green light committee (GLC) program. The study aimed (1) to describe the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoa, Nguyen Binh, Nhung, Nguyen Viet, Khanh, Pham Huyen, Hai, Nguyen Viet, Quyen, Bui Thi Tu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687360/
https://www.ncbi.nlm.nih.gov/pubmed/26695761
http://dx.doi.org/10.1186/s13104-015-1806-4
_version_ 1782406620706242560
author Hoa, Nguyen Binh
Nhung, Nguyen Viet
Khanh, Pham Huyen
Hai, Nguyen Viet
Quyen, Bui Thi Tu
author_facet Hoa, Nguyen Binh
Nhung, Nguyen Viet
Khanh, Pham Huyen
Hai, Nguyen Viet
Quyen, Bui Thi Tu
author_sort Hoa, Nguyen Binh
collection PubMed
description BACKGROUND: Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the green light committee (GLC) program. The study aimed (1) to describe the strengths and weaknesses of treatment of GLC and non-GLC MDR-TB patients as well as the factors influencing treatment completion and (2) to determine the incidence of adverse drug reactions. RESULTS: This cross-sectional study comprised two elements: (1) in-depth interviews with clinical doctors, hospital pharmacists; and focus group discussions with MDR-TB patients; and (2) a review of the charts of all GLC and non-GLC MDR-TB patients in 2010. A total of 282 MDR-TB patients were recruited, including 79(28 %) MDR-TB patients treated through the GLC program and 203(72 %) MDR-TB patients treated outside of the GLC program. The main strengths of GLC treatment were the supply of quality assured second line TB drugs, routine monitoring and clinical evaluation, free diagnostic tests and close clinical monitoring. The greatest barriers to patients treated outside of the GLC program was difficulty paying for second line TB drugs and other treatment costs. There was no significant difference between the incidence of adverse events among GLC (46.8 %) and non-GLC treated patients (52.2 %; p = 0.417). Among 143 patients who reported 226 adverse reaction events, arthralgia/joint pain (35.8 %), gastrointestinal (14.2 %), ototoxicity (8.4 %), cutaneous (6.6 %), and giddiness (5.8 %) were the most common. CONCLUSIONS: The non-GLC MDR-TB patients face substantial barriers to treatment, and require greater support if they are to complete treatment and improve disease outcomes. Staff training about the management of adverse drug reactions is needed.
format Online
Article
Text
id pubmed-4687360
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46873602015-12-23 Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam Hoa, Nguyen Binh Nhung, Nguyen Viet Khanh, Pham Huyen Hai, Nguyen Viet Quyen, Bui Thi Tu BMC Res Notes Research Article BACKGROUND: Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the green light committee (GLC) program. The study aimed (1) to describe the strengths and weaknesses of treatment of GLC and non-GLC MDR-TB patients as well as the factors influencing treatment completion and (2) to determine the incidence of adverse drug reactions. RESULTS: This cross-sectional study comprised two elements: (1) in-depth interviews with clinical doctors, hospital pharmacists; and focus group discussions with MDR-TB patients; and (2) a review of the charts of all GLC and non-GLC MDR-TB patients in 2010. A total of 282 MDR-TB patients were recruited, including 79(28 %) MDR-TB patients treated through the GLC program and 203(72 %) MDR-TB patients treated outside of the GLC program. The main strengths of GLC treatment were the supply of quality assured second line TB drugs, routine monitoring and clinical evaluation, free diagnostic tests and close clinical monitoring. The greatest barriers to patients treated outside of the GLC program was difficulty paying for second line TB drugs and other treatment costs. There was no significant difference between the incidence of adverse events among GLC (46.8 %) and non-GLC treated patients (52.2 %; p = 0.417). Among 143 patients who reported 226 adverse reaction events, arthralgia/joint pain (35.8 %), gastrointestinal (14.2 %), ototoxicity (8.4 %), cutaneous (6.6 %), and giddiness (5.8 %) were the most common. CONCLUSIONS: The non-GLC MDR-TB patients face substantial barriers to treatment, and require greater support if they are to complete treatment and improve disease outcomes. Staff training about the management of adverse drug reactions is needed. BioMed Central 2015-12-22 /pmc/articles/PMC4687360/ /pubmed/26695761 http://dx.doi.org/10.1186/s13104-015-1806-4 Text en © Hoa et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hoa, Nguyen Binh
Nhung, Nguyen Viet
Khanh, Pham Huyen
Hai, Nguyen Viet
Quyen, Bui Thi Tu
Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title_full Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title_fullStr Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title_full_unstemmed Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title_short Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
title_sort adverse events in the treatment of mdr-tb patients within and outside the ntp in pham ngoc thach hospital, ho chi minh city, vietnam
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687360/
https://www.ncbi.nlm.nih.gov/pubmed/26695761
http://dx.doi.org/10.1186/s13104-015-1806-4
work_keys_str_mv AT hoanguyenbinh adverseeventsinthetreatmentofmdrtbpatientswithinandoutsidethentpinphamngocthachhospitalhochiminhcityvietnam
AT nhungnguyenviet adverseeventsinthetreatmentofmdrtbpatientswithinandoutsidethentpinphamngocthachhospitalhochiminhcityvietnam
AT khanhphamhuyen adverseeventsinthetreatmentofmdrtbpatientswithinandoutsidethentpinphamngocthachhospitalhochiminhcityvietnam
AT hainguyenviet adverseeventsinthetreatmentofmdrtbpatientswithinandoutsidethentpinphamngocthachhospitalhochiminhcityvietnam
AT quyenbuithitu adverseeventsinthetreatmentofmdrtbpatientswithinandoutsidethentpinphamngocthachhospitalhochiminhcityvietnam